AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00380237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Description: Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
Study NCT00572377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FemLife Gel
Description: the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Study NCT00572377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Study NCT03961334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: 150mg 2x/d
Study NCT03961334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5mg 2x/d
Study NCT03961334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 60mg 1x/d
Study NCT03961334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg 1x/d
Study NCT03961334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg 1x/d
Study NCT00826644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan
Description: Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
Study NCT00826644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
Study NCT00826644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
Study NCT00826644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
Study NCT02174731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Study NCT02174731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Study NCT02799901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionned radiotherapy
Description: radiation
Study NCT00605852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK835726
Description: GSK835726 will be available in single dose and repeat dose formulations.
Study NCT00605852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to subjects.
Study NCT00605852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to subjects.
Study NCT00936234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
Study NCT00936234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
Study NCT03960541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)
Description: Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
Study NCT03960541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
Study NCT03382717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excilor Forte
Description: 1 application per day during 6 months
Study NCT03382717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl 5%
Description: 1 application per week during 6 months
Study NCT00534326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Reaming
Description: Femoral reaming using standard reaming techniques of multiple reamers
Study NCT00534326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reaming/Irrigating/Aspirating
Description: Reaming using the Reamer/Irrigator/Aspirating
Study NCT02682953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Pharmacological agents often used for stem cell mobilization will be utilized in this study.
Study NCT02682953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
Study NCT02682953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Pharmacological agents often used for stem cell mobilization will be utilized in this study.
Study NCT03398304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Exercise
Description: Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
Study NCT03398304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marathon participation
Description: Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
Study NCT03080155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA Device imaging for adjunctive detection of breast cancer
Study NCT04182945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection for algorithm development
Description: 50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
Study NCT02617680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane - oxygen in air
Description: The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
Study NCT02617680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane - oxygen in nitric oxide
Description: The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
Study NCT03808090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal Individuals
Description: Controlled Dietary phase: Low oxalate fixed diet~4 days of fixed normal calorie diet with low oxalate (\< 60 mg/day), normal calcium (800-1200 mg/day)
Study NCT00525720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy implant procedure lasting 1-2 hours.
Study NCT00525720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 30 total minutes.
Study NCT01213394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)
Study NCT01213394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard immunosuppression
Description: Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
Study NCT03236896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
Study NCT03236896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
Study NCT02113709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion therapy by Eye Patch
Description: The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
Study NCT02113709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion therapy
Description: To see how much improvement in visual acuity occurs by full-time occlusion therapy.
Study NCT04219774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular intervention
Description: Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
Study NCT04219774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Clopidogrel (maximal medical Therapy)
Description: Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
Study NCT02893293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol-enhanced magnetic resonance imaging
Description: Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
Study NCT02893293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magentic Resonance Imaging
Description: Both arms will receive MRI
Study NCT02893293 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magentic Resonance Imaging
Description: Both arms will receive MRI
Study NCT01806220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of the retrocrycoid laryngeal mucosa
Description: Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
Study NCT01806220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of the distal esophageal mucosa
Description: Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
Study NCT01404169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
Study NCT01404169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
Study NCT02639494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Centering Guide Catheter
Study NCT02501915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 2 mg/kg
Description: On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
Study NCT00740987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression of the lower limbs
Description: No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
Study NCT00901823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Description: A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
Study NCT00901823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline high dose
Description: A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
Study NCT04320706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Oxytocin
Description: Administration of oxytocin (24 international units) orally
Study NCT04320706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Administration of placebo orally
Study NCT01080833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP mechanical simulator practice
Description: Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
Study NCT01526031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1:10,000 bee venom (BV) acupuncture
Description: after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)
Study NCT01526031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1:30,000 bee venom (BV) acupuncture
Description: after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)
Study NCT01526031 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: normal saline injection
Description: after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)
Study NCT01526031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program
Study NCT01526031 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy
Description: Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program
Study NCT02376374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlling vaccination rates in communities
Description: Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
Study NCT01134120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 6/2 mg/kg
Description: A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 6/6 mg/kg
Description: A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 4 mg/kg
Description: On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
Study NCT01033240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS-1008 6 mg/kg
Description: On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: 48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
Study NCT00074165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dose: 40mg on Day 14 following chemotherapy
Study NCT02494193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial caries removal
Description: The caries infected dentin will be removed mantaining the affected caries tissue.
Study NCT02494193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial caries removal
Description: The caries infected dentin will be removed mantaining the affected caries tissue.
Study NCT02494193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provisional restoration - control
Description: After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
Study NCT02494193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provisional restoration - experimental
Description: After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.